PV Bulletin

Psychedelic Drugs: Considerations for Clinical Investigations

The FDA's final guidance document outlines considerations for clinical investigations of psychedelic drugs, focusing on safety and abuse potential.

Primary source: Advisory Committee Guidance Documents

PV Impact Brief

Urgency: HighConfidence: high

What changed

The FDA published final guidance detailing specific requirements for clinical trials involving psychedelic drugs, effective from July 2026.

Why it matters

As interest in the therapeutic potential of psychedelic drugs grows, adhering to these FDA recommendations is vital for ensuring participant safety and regulatory compliance.

Action needed

Clinical safety and pharmacovigilance teams must implement new safety monitoring protocols and ensure adequate assessment of abuse potential as stipulated in the guidance.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Guideline
Policy status
final
Publication date
2026-07-13
Policy change
This final guidance outlines the FDA's considerations for clinical investigations of psychedelic drugs, emphasizing safety monitoring and the assessment of abuse potential.

Key changes

Provides recommendations on clinical trial design, including blinding, the role of psychotherapy, and safety monitoring requirements for drugs with potential psychoactive effects. It addresses the unique safety profile of psychedelics and the need for robust adverse event collection.

Affected workflows

Country Compliance

Responsible groups

Clinical SafetyPharmacovigilance OperationsRegulatory Affairs

PV impact

Clinical safety and PV teams must ensure that safety monitoring protocols for trials involving psychedelics comply with these specific FDA recommendations, particularly regarding the detection and reporting of psychoactive side effects and abuse potential.

View regulator source

Source document details

Exact policy details

Docket Number
FDA-2023-D-1987
Applies to: Applicable to clinical trials for psychedelic drugs.
Docket Number: FDA-2023-D-1987 · p. 1 · High · Source
Guidance Published Date
July 2026
Applies to: The guidance is effective from this date.
Published at: July 2026 · p. 1 · High · Source
Nonclinical Program Requirement
Follow ICH guidance M3(R2)
Applies to: Nonclinical studies for psychedelic drugs should align with ICH guidelines.
The nonclinical program for psychedelic drugs should follow recommendations outlined in the ICH guidance for industry M3(R2). · p. 7 · High · Source
IND Inclusion Requirements
Pharmacological and toxicological studies are required
Applies to: An IND must include adequate safety information before initiating human trials.
An IND must include adequate information about pharmacological and toxicological studies. · p. 7 · High · Source
Abuse Potential Assessment Requirement
Abuse potential evaluation is mandatory
Applies to: All new drug applications must include an assessment of abuse potential.
The assessment of the abuse potential of a drug product under development is generally conducted as a component of its safety evaluation. · p. 10 · High · Source

Workflow rule impacts

Country ComplianceCompliance Department

Increased regulatory scrutiny due to Schedule I status of certain psychedelic compounds.

Need to assess compliance with controlled substances regulations.

Activities associated with investigations under an IND must comply with the Controlled Substances Act. · p. 10 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 13, 2026

Full briefing

Practical implication

Clinical safety and pharmacovigilance teams must implement new safety monitoring protocols and ensure adequate assessment of abuse potential as stipulated in the guidance.

The FDA has issued final guidance detailing the necessary considerations for clinical investigations of psychedelic drugs, emphasizing robust safety monitoring protocols and abuse potential assessments. This guidance is crucial for teams engaged in the clinical evaluation of these substances.

What changed: The FDA published final guidance detailing specific requirements for clinical trials involving psychedelic drugs, effective from July 2026.

Why it matters: As interest in the therapeutic potential of psychedelic drugs grows, adhering to these FDA recommendations is vital for ensuring participant safety and regulatory compliance.

Practical implication: Clinical safety and pharmacovigilance teams must implement new safety monitoring protocols and ensure adequate assessment of abuse potential as stipulated in the guidance.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Guideline#final#Food and Drug Administration#reporting_requirement#policy-change#firecrawl-policy-agent

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward